Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 413

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 413
---
| Exercise price of warrants issued in year  |     |   | $232.00/$400.00 |     |     | $ |         15.00 |     |     | $ |          2.50 |     |
| Contractual life                           |     |   |         3 years |     |     |   |       3 years |     |     |   |       3 years |     |
| Expected life                              |     |   |         3 years |     |     |   |       3 years |     |     |   |       3 years |     |
| Volatility                                 |     |   |           75.00 | %** |     |   |         80.00 | %** |     |   |            60 | %** |
| Expected dividend yield                    |     |   |               0 | %   |     |   |             0 | %   |     |   |             0 | %   |
| Risk free rate                             |     |   |            4.35 | %   |     |   |          4.04 | %   |     |   |          4.06 | %   |

| * | The share price used in the determination of the fair value of the ADS warrants granted in 2023 was the ADS price on the date of grant. |

| F-76 |

| 25 | Capital commitments |

The Group had no capital
commitments at 31 December 2023, 31 December 2022 and 31 December 2021.

| 26 | Related party transactions |

There were no related party transactions in the current
or prior periods other than Directors’ remuneration.

| 27 | Contingent liabilities |

The Company entered
into an Arrangement Agreement with Bioasis on 13 December 2022 as amended on 18 December 2022. Under the agreement the Company agreed
to acquire the entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$7.4 million (c£4.4 million).
The agreement was subject to shareholder approval. On 23 January 2023 at the General Meeting to approve the Arrangement Agreement none
of the special resolutions were passed and, accordingly, the acquisition of Bioasis did not proceed. Under the agreement the Company agreed
to reimburse Bioasis US$225,000 expenses relating to the transaction should the Company’s shareholders not approve the transaction.
On